Skip to content Skip to footer
Subscribe Now
NEWS

PulseSight Therapeutics Reports First Patient Dosing with PST-611 in P-I (PST-611-CT1) Trial for Dry AMD/Geographic Atrophy 

Shots: PulseSight Therapeutics has dosed first pts in the P-I (PST-611-CT1) trial to assess safety & tolerability of PST-611 in humans The P-I single ascending dose study will evaluate safety & determine maximum tolerated dose of PST-611 for P-IIa trial in 6–12 pts with dry age-related macular degeneration/geographic atrophy pts, with preliminary results expected in…
July 7, 2025

Read more

Astellas
NEWS

Japan’s MHLW Receives NDA for Conditional Approval of Astellas’ Avacincaptad Pegol to Treat Geographic Atrophy

Shots: Japan’s MHLW has received NDA for conditional approval of avacincaptad pegol (ACP) to treat geographic atrophy (GA) secondary to AMD Submission was backed by the P-II/III (GATHER1) & P-III (GATHER2) trials assessing safety & efficacy of ACP (2mg, Q1M, intravitreal) in pts with GA secondary to AMD Data from both trials showed reduced…
February 5, 2025

Read more

PharmShots Interview In Conversation with Nancy Holekamp, Director of Retina Services, Where she Shares Insights on The Results of the Global Survey to Find the Impact of Geographic Atrophy
VIEWPOINTS

PharmShots Interview: In Conversation with Nancy Holekamp, Director of Retina Services, Where she Shares Insights on The Results of the Global Survey to Find the Impact of Geographic Atrophy

Shots: Nancy spoke about the results from the Geographic Atrophy Insights Survey (GAINS) Nancy also talked about the emotional burden on the patients and the devastating impact on independence caused by vision loss  The global survey was conducted by The Harris Poll on behalf of Apellis Pharmaceuticals to find the impact of GA which is a…
July 6, 2022

Read more